Fosamprenavir contraindications: Difference between revisions
Jump to navigation
Jump to search
Ahmed Zaghw (talk | contribs) No edit summary |
Ahmed Zaghw (talk | contribs) |
||
| Line 8: | Line 8: | ||
LEXIVA is contraindicated: | LEXIVA is contraindicated: | ||
*:In patients with previously demonstrated clinically significant hypersensitivity (e.g., Stevens-Johnson syndrome) to any of the components of this product or to amprenavir. | *:In patients with previously demonstrated clinically significant [[hypersensitivity]] (e.g., [[Stevens-Johnson syndrome]]) to any of the components of this product or to amprenavir. | ||
*:When coadministered with drugs that are highly dependent on cytochrome P450 3A4 (CYP3A4) for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events (Table 2).<ref>{{Cite web | last = | first = | title = LEXIVA (FOSAMPRENAVIR CALCIUM) TABLET, FILM COATED LEXIVA (FOSAMPRENAVIR CALCIUM) SUSPENSION [VIIV HEALTHCARE COMPANY] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=24feb9be-32a6-45fd-a896-f3e202edd8a9 | publisher = | date = | accessdate = }}</ref> | *:When coadministered with drugs that are highly dependent on [[cytochrome P450]] 3A4 (CYP3A4) for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events (Table 2).<ref>{{Cite web | last = | first = | title = LEXIVA (FOSAMPRENAVIR CALCIUM) TABLET, FILM COATED LEXIVA (FOSAMPRENAVIR CALCIUM) SUSPENSION [VIIV HEALTHCARE COMPANY] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=24feb9be-32a6-45fd-a896-f3e202edd8a9 | publisher = | date = | accessdate = }}</ref> | ||
{| | {| | ||
Revision as of 01:46, 4 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Contraindications
LEXIVA is contraindicated:
- In patients with previously demonstrated clinically significant hypersensitivity (e.g., Stevens-Johnson syndrome) to any of the components of this product or to amprenavir.
- When coadministered with drugs that are highly dependent on cytochrome P450 3A4 (CYP3A4) for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events (Table 2).[1]
 |
References
Adapted from the FDA Package Insert.